ATX Stock Discussion
Amplia Therapeutics Limited Description
Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3). FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
Industry: Biotechnology
Keywords: Health Medicine Pharmaceutical Disease Cancer Diseases Drugs Oncology Tumor Chemotherapy Tumors Chronic Disease Fibrosis Ovarian Cancer Chronic Diseases Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis
Recent Comments
- SwingTradeBot on Market Recap for Wednesday, February 28, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
- SwingTradeBot on Market Recap for Monday, February 26, 2024
- SwingTradeBot on Market Recap for Friday, February 23, 2024
- SwingTradeBot on Market Recap for Thursday, February 22, 2024
From the Blog
Featured Articles